- Email: [email protected]
8703300 Enhanced secretion of heterologous proteins by hosts using substituted promoters
PATENT ABSTRACTS
318 8703008 SHORTENED PHOSPHOGLYCERATE PROMOTER
8703300
KINASE
Jar-How LEE. Lindley BLAIR, Arnold HORWITZ, Raju Kanaka KODURI assigned to INTERNATIONAL GENETIC ENGINEERING INC: A shortened PGK promoter of the PGK gene comprising less than 500 base pairs of the proximal end of the 5" region of the PGK gene. The invention also provides for vehicles capable of replication and expression comprising said shortened PGK promoter operably linked to a structural gene and operably linked to a secretion signal linked to a structural gene, and also provides for hosts transformed with the vehicle. In one embodiment of the invention disclosed, the shortened PGK promoter is used with a process for regulating yeast plasmid copy number by two seleetable markers, the first marker having normal or high level expression from its promoter, the second marker, leu2-d, having low level expression from its promoter. Expression of a structural gene on this plasmid system can be increased by lowering the level of the second metabolite (leucine) in the growth medium, thereby selecting for an increased copy number of the second selectable marker (leu2-d), and therefore increased plasmid copy number, which in turn increases the number of copies of the structural gene being expressed.
ENHANCED SECRETION OF HETEROLOGOUS PROTEINS BY HOSTS USING SUBSTITUTED PROMOTERS Joachim F ERNST, Ursula SCHMEISSNER, 156, chemin des Marais, CH-1255 Veyrier, Switzerland assigned to BIOGEN N V: Improved secretion of heterologous proteins by hosts such as yeast by using promoters of at most intermediate strength with heterologous DNA secretion signal sequences. A promoter of at most intermediate strength, such as the actin (ACT) or iso-l-cytochrome c (CYCI) promoter in S. cerevisiae) is operatively linked to a DNA signal sequence, such as the MF g(al) signal sequence. A DNA sequence for a selected protein. such as somatomedin C (SMC), tissue plasminogen activator (TPA) or tumor necrosis factor (TNF), may be operatively linked to the DNA signal sequence.
8703301 PURIFIED ANTIGENS HAVING VACCINATING PROPERTIES A G A I N S T B. P E R T U S S I S , M E A N S , PARTICULARLY RECOMBINANT DNAS F O R P R O D U C I N G T H E M , AND VACCINE COMPOSITIONS CONTAINING THEM
8703298 METHOD FOR GENETICALLY MARKING YEAST George Desmond CLARK-WALKER, 9 Chermside Street, Deakin, ACT 2600. Australia assigned to THE AUSTRALIAN NATIONAL UNIVERSITY A genetically marked strain of the yeast Saccharomyces cerevisiae) is characterised in that the mithochondrial (mt)DNA of the yeast has been rearranged by recombination. A method of producing such a strain is also disclosed.
Agn@s ULLMANN, Denise MATTEI, Odile MERCEREAU-PUIJALON, Jean-Michel ALONSO, OZAKI Luiz SHOZO, Fr(a d(a rique PICHOT, 3, rue Paul Dupuy, E-75016 Paris, France assigned to INSTITUT PASTEUR Polypeptides capable of forming active principals of purified vaccines against wooping-cough. They are produced by genetic engineering. They are recognized by anti-FHA, anti-LPF and antiCYA antibodies. The invention also relates to DNA sequences coding for said polypeptides, as well as to immunogen¢ compositions associating said polypeptides with pharmaceutically acceptable vehicles.
318 8703008 SHORTENED PHOSPHOGLYCERATE PROMOTER
8703300
KINASE
Jar-How LEE. Lindley BLAIR, Arnold HORWITZ, Raju Kanaka KODURI assigned to INTERNATIONAL GENETIC ENGINEERING INC: A shortened PGK promoter of the PGK gene comprising less than 500 base pairs of the proximal end of the 5" region of the PGK gene. The invention also provides for vehicles capable of replication and expression comprising said shortened PGK promoter operably linked to a structural gene and operably linked to a secretion signal linked to a structural gene, and also provides for hosts transformed with the vehicle. In one embodiment of the invention disclosed, the shortened PGK promoter is used with a process for regulating yeast plasmid copy number by two seleetable markers, the first marker having normal or high level expression from its promoter, the second marker, leu2-d, having low level expression from its promoter. Expression of a structural gene on this plasmid system can be increased by lowering the level of the second metabolite (leucine) in the growth medium, thereby selecting for an increased copy number of the second selectable marker (leu2-d), and therefore increased plasmid copy number, which in turn increases the number of copies of the structural gene being expressed.
ENHANCED SECRETION OF HETEROLOGOUS PROTEINS BY HOSTS USING SUBSTITUTED PROMOTERS Joachim F ERNST, Ursula SCHMEISSNER, 156, chemin des Marais, CH-1255 Veyrier, Switzerland assigned to BIOGEN N V: Improved secretion of heterologous proteins by hosts such as yeast by using promoters of at most intermediate strength with heterologous DNA secretion signal sequences. A promoter of at most intermediate strength, such as the actin (ACT) or iso-l-cytochrome c (CYCI) promoter in S. cerevisiae) is operatively linked to a DNA signal sequence, such as the MF g(al) signal sequence. A DNA sequence for a selected protein. such as somatomedin C (SMC), tissue plasminogen activator (TPA) or tumor necrosis factor (TNF), may be operatively linked to the DNA signal sequence.
8703301 PURIFIED ANTIGENS HAVING VACCINATING PROPERTIES A G A I N S T B. P E R T U S S I S , M E A N S , PARTICULARLY RECOMBINANT DNAS F O R P R O D U C I N G T H E M , AND VACCINE COMPOSITIONS CONTAINING THEM
8703298 METHOD FOR GENETICALLY MARKING YEAST George Desmond CLARK-WALKER, 9 Chermside Street, Deakin, ACT 2600. Australia assigned to THE AUSTRALIAN NATIONAL UNIVERSITY A genetically marked strain of the yeast Saccharomyces cerevisiae) is characterised in that the mithochondrial (mt)DNA of the yeast has been rearranged by recombination. A method of producing such a strain is also disclosed.
Agn@s ULLMANN, Denise MATTEI, Odile MERCEREAU-PUIJALON, Jean-Michel ALONSO, OZAKI Luiz SHOZO, Fr(a d(a rique PICHOT, 3, rue Paul Dupuy, E-75016 Paris, France assigned to INSTITUT PASTEUR Polypeptides capable of forming active principals of purified vaccines against wooping-cough. They are produced by genetic engineering. They are recognized by anti-FHA, anti-LPF and antiCYA antibodies. The invention also relates to DNA sequences coding for said polypeptides, as well as to immunogen¢ compositions associating said polypeptides with pharmaceutically acceptable vehicles.